The discontinuation of STRIDES is a rare stumble for the next-generation obesity field and comes just weeks after Amgen ...

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...

Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

Wall Street is chewing over data on Amgen’s weight loss injection, MariTde. Meanwhile, GE HealthCare will acquire a Japanese ...

According to phase 2 study, MariTide achieved significant weight loss in individuals with obesity or overweight, with up to ...

It is not clear what specifically the new facility will produce, though Amgen could be ramping up its manufacturing capacity ...

The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...